The COVID-19 pandemic is having profound mental health consequences for many people. Concerns have been expressed that, at their most extreme, these consequences could manifest as increased suicide rates. In this article the authors aimed to assess the early effect of the COVID-19 pandemic on suicide rates around the world.

In this phase 1, double-blind, placebo-controlled, block-randomised trial the authors aimed to assess the safety and immunogenicity of an MF59-adjuvanted subunit vaccine for COVID-19 based on recombinant SARS-CoV-2 spike glycoprotein stabilised in a pre-fusion conformation by a novel molecular clamp.

CEREBRAL VENOUS THROMBOSIS AFTER VACCINATION AGAINST SARS-CoV-2: The International Cerebral Venous Thrombosis Consortium (ICVTC) registry

Virtual 2021: Which Session You Should Not Miss

CoV2 preS dTM is a stabilised pre-fusion spike protein vaccine produced in a baculovirus expression system being developed against SARS-CoV-2. In this phase 1–2, randomised, double-blind study the authors present interim safety and immunogenicity results of the first-in-human study of the CoV2 preS dTM vaccine with two different adjuvant formulations.

In this article the authors examined vaccine effectiveness among health care workers at the Hadassah Hebrew University Medical Center (HHUMC), a two-campus medical center in Jerusalem that employs 6680 people.

Since the start of the vaccination campaign, the development of COVID-19 has been reported in persons who have received one or both doses of mRNA-1273 (Moderna) or BNT162b2 (Pfizer) vaccine.

Authors describe mRNA1273-elicited binding and neutralizing antibodies in 33 healthy adults in an ongoing phase 1 trial, 180 days after the second dose of 100 μg (day 209).

Whether or not people who have been infected SARS-CoV-2 should be vaccinated is unclear. This observational cohort study, the authors enrolled 100 health care workers, including 38 with a documented history of SARS-CoV-2 infection.

In this article, the authors report findings in five patients who presented with venous thrombosis and thrombocytopenia 7 to 10 days after receiving the first dose of the ChAdOx1nCoV-19 adenoviral vector vaccine against COVID-19.

In this article, the authors report findings in 23 patients who presented with thrombosis and thrombocytopenia 6 to 24 days after receiving the first dose of the ChAdOx1 nCoV-19 vaccine (AstraZeneca).

In this article the authors assessed the clinical and laboratory features of 11 patients in Germany and Austria in whom thrombosis or thrombocytopenia had developed after vaccination with ChAdOx1 nCov-19.

EAN members receive free access to the ebrain learning platform. The website has a new look and layout for 2021 plus a new podcast series – “Ten Minute Urgent Neurology” by Adrian Wills, ebrain Clinical Lead.

Patient involvement in the education of healthcare professionals has been identified already several years ago as a priority[1][1] to ensure the future health workforce have the skills, knowledge and attitudes to practice truly person-centred care – including shared decision-making, listening, supportive and effective communication, empathy and partnership.